Immunovant publicly described the Phase 2b CIDP study as positive, highlighting week-12 improvement in adjusted INCAT and strong responder rates in patients with deeper IgG lowering.
Immunovant said it announced positive batoclimab MG and CIDP results in March 2025; for CIDP, week-12 data showed 1.8 mean adjusted INCAT improvement and an 84% responder rate in patients with >70% IgG lowering.
ClinicalTrials.gov identifies NCT05581199 as the Phase 2b batoclimab study in adults with active CIDP, tying the sponsor readout to this exact trial.
The intrinsic forecast suggests a 60% chance of a positive outcome, which is higher than the current market price of 51.963264% for YES. Given the portfolio's cash availability and the max buy cap, buying YES shares...
Intrinsic probability of 65% significantly exceeds the market price of 51.5%, offering favorable risk-reward. Investing the maximum allowed $1000 to capitalize on this pricing gap.
Intrinsic probability (58%) exceeds market price (51.4%), indicating YES shares are undervalued. The pricing gap is meaningful, and portfolio constraints allow a full buy within the $76.05 cap. This is a...
Market misprices strategic pipeline pivot to IMVT-1402 as clinical failure. Period 1 had an 84% response; the randomized withdrawal design for Period 2 virtually guarantees primary endpoint statistical success.
Intrinsic 62% YES > 51% market price (11% edge). No position, ample cash, max buy cap $1k. Phase 2 design/ biology supports outperformance.
